Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Felix

Showing results (21-30 of 42) with videos related to

Pageof 5
Sort By:
European Heart Journal|May 14, 2022
Twitter promotion is associated with higher citation rates of cardiovascular articles: the ESC Journals Randomized StudyRicardo Ladeiras-Lopes, Rafael Vidal-Perez, Diogo Santos-Ferreira, et al.
Biological & Pharmaceutical Bulletin|June 4, 2013
Caffeic acid phenethyl ester inhibits endothelial tissue factor expressionCathérine Gebhard, Barbara Elisabeth Stähli, Stephanie Largiadèr, et al.
International Journal of Cardiology|July 27, 2018
Hyperglycaemia-induced epigenetic changes drive persistent cardiac dysfunction via the adaptor p66<sup>Shc</sup>Sarah Costantino, Francesco Paneni, Katharyn Mitchell, et al.
BMJ Open|September 22, 2016
Uptake and efficacy of a systematic intensive smoking cessation intervention using motivational interviewing for smokers hospitalised for an acute coronary syndrome: a multicentre before-after study with parallel group comparisonsReto Auer, Baris Gencer, Rodrigo Tango, et al.
Circulation|October 27, 2004
Deletion of p66shc gene protects against age-related endothelial dysfunctionPietro Francia, Chiara delli Gatti, Markus Bachschmid, et al.
Scientific Reports|June 10, 2020
Author Correction: Downstream Products are Potent Inhibitors of the Heparan Sulfate 2-O-SulfotransferaseDavid F Thieker, Yongmei Xu, Digantkumar Chapla, et al.
Scientific Reports|August 9, 2018
Downstream Products are Potent Inhibitors of the Heparan Sulfate 2-O-SulfotransferaseDavid F Thieker, Yongmei Xu, Digantkumar Chapla, et al.
Theranostics|July 23, 2015
Doxycycline Inducible Melanogenic Vaccinia Virus as Theranostic Anti-Cancer AgentLorenz Kirscher, Xosé Luis Deán-Ben, Miriam Scadeng, et al.
European Heart Journal|May 29, 2009
A randomized placebo-controlled study on the effect of nifedipine on coronary endothelial function and plaque formation in patients with coronary artery disease: the ENCORE II studyThomas Felix Lüscher, Michael Pieper, Michael Tendera, et al.
European Journal of Preventive Cardiology|October 25, 2024
Safety of beta-blocker discontinuation after acute coronary syndromes with preserved or mildly reduced left ventricular ejection fraction: a target trial emulation from a real-world cohortNicolas Johner, Mattia Branca, David Carballo, et al.
Pageof 5

Showing results (21-30 of 42) with videos related to

Sort By:
Pageof 5
European Heart Journal|May 14, 2022
Twitter promotion is associated with higher citation rates of cardiovascular articles: the ESC Journals Randomized StudyRicardo Ladeiras-Lopes, Rafael Vidal-Perez, Diogo Santos-Ferreira, et al.
Biological & Pharmaceutical Bulletin|June 4, 2013
Caffeic acid phenethyl ester inhibits endothelial tissue factor expressionCathérine Gebhard, Barbara Elisabeth Stähli, Stephanie Largiadèr, et al.
International Journal of Cardiology|July 27, 2018
Hyperglycaemia-induced epigenetic changes drive persistent cardiac dysfunction via the adaptor p66<sup>Shc</sup>Sarah Costantino, Francesco Paneni, Katharyn Mitchell, et al.
BMJ Open|September 22, 2016
Uptake and efficacy of a systematic intensive smoking cessation intervention using motivational interviewing for smokers hospitalised for an acute coronary syndrome: a multicentre before-after study with parallel group comparisonsReto Auer, Baris Gencer, Rodrigo Tango, et al.
Circulation|October 27, 2004
Deletion of p66shc gene protects against age-related endothelial dysfunctionPietro Francia, Chiara delli Gatti, Markus Bachschmid, et al.
Scientific Reports|June 10, 2020
Author Correction: Downstream Products are Potent Inhibitors of the Heparan Sulfate 2-O-SulfotransferaseDavid F Thieker, Yongmei Xu, Digantkumar Chapla, et al.
Scientific Reports|August 9, 2018
Downstream Products are Potent Inhibitors of the Heparan Sulfate 2-O-SulfotransferaseDavid F Thieker, Yongmei Xu, Digantkumar Chapla, et al.
Theranostics|July 23, 2015
Doxycycline Inducible Melanogenic Vaccinia Virus as Theranostic Anti-Cancer AgentLorenz Kirscher, Xosé Luis Deán-Ben, Miriam Scadeng, et al.
European Heart Journal|May 29, 2009
A randomized placebo-controlled study on the effect of nifedipine on coronary endothelial function and plaque formation in patients with coronary artery disease: the ENCORE II studyThomas Felix Lüscher, Michael Pieper, Michael Tendera, et al.
European Journal of Preventive Cardiology|October 25, 2024
Safety of beta-blocker discontinuation after acute coronary syndromes with preserved or mildly reduced left ventricular ejection fraction: a target trial emulation from a real-world cohortNicolas Johner, Mattia Branca, David Carballo, et al.
Pageof 5